Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.65 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.61 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924993 | 0.94 | CACNA1H (0.70) | MCHR1CACNA1HCACNA1BGAAALDH1A1 | |
| SCHEMBL6926500 | 0.87 | MCHR1 (0.69) | MCHR1CACNA1HCACNA1BGAA | |
| SCHEMBL6924996 | 0.81 | GAA (0.51) | MCHR1CACNA1HCACNA1BGAAALDH1A1 | |
| SCHEMBL16119541 | 0.81 | EPHX1 (0.56) | CACNA1HCACNA1BALDH1A1KDM4EKMT2A | |
| SCHEMBL6927664 | 0.80 | MCHR1 (0.61) | MCHR1CACNA1HCACNA1BGAAALDH1A1 | |
| SCHEMBL6921976 | 0.80 | MCHR1 (0.77) | MCHR1CACNA1HCACNA1BALDH1A1KDM4E | |
| SCHEMBL6920369 | 0.80 | MCHR1 (0.68) | MCHR1SMN1; SMN2KMT2A | |
| SCHEMBL5183311 | 0.80 | GAA (0.66) | CACNA1HCACNA1BGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL3500701 | 0.80 | GAA (0.60) | MCHR1CACNA1HCACNA1BGAAALDH1A1 | |
| SCHEMBL6928640 | 0.79 | MCHR1 (0.92) | MCHR1ALDH1A1KDM4EHTR7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | claimed |
| JP-2002511879-A | — | — | 2002-04-16 | — | — | JP | claimed |
| EP-1001766-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2001-04-04 | — | — | EP | claimed |
| EP-1001766-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999001127-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | disclosed |
| EP-1001766-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1001766-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999001127-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |